Navigation Links
MolecularHealth and FDA to Collaborate on Analytical Tools for Mechanism-Based Drug Safety Assessment
Date:2/14/2012

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- MolecularHealth, Inc., a leader in clinico-molecular informatics™, today announced the establishment of a five-year research collaboration agreement with the U.S. Food and Drug Administration (FDA) to evaluate and refine MolecularHealth's Molecular Analysis of Side Effects (MASE), a software system intended to support mechanism-based drug safety assessment and prediction.

The FDA's Center for Drug Evaluation and Research (CDER) will work with MolecularHealth to incorporate non-proprietary molecular and clinical endpoints of regulatory interest into MASE, along with non-proprietary information on patient populations, drug promiscuity, molecular modes of action and mechanisms of disease.

"We are pleased to collaborate with the FDA to obtain their input into the evaluation of the analytical power of MASE for assessing drug safety in the U.S.," said Jeffrey D. Marrazzo, chief business officer of MolecularHealth. "MASE has the potential to benefit pharmaceutical developers, regulators and clinicians alike, helping them to develop and monitor drugs in a safer, more efficient manner."

MASE uses information about drug modes of action and the molecular implications of interacting treatments, co-morbidities and genetic profiles to enable a more precise assessment of drug safety. MASE enables the exploration and analysis of adverse event information from both statistical and molecular perspectives and provides analytical and visualization tools to support the detection and validation of drug-related safety issues.

"Drug safety monitoring and detection have become increasingly important and complex endeavors that depend heavily on a static, binary, observational system," said David Jackson, chief scientific officer of MolecularHealth. "We believe that MolecularHealth's predictive approach to understanding the molecular basis of adverse events will complement the agency's current mode of drug safety assessment to advance the promise of precision medicine."

About MolecularHealthMolecularHealth, Inc., a clinico-molecular informatics company, is advancing precision medicine by translating patient-specific molecular and genomic data, clinical history and published scientific and medical evidence into safer, more effective drug choices for patients. The company's solutions range from a next generation drug safety assessment and prediction tool that analyzes the molecular basis of adverse events to a treatment decision support system that transforms genome sequences into evidence-based treatment strategies for cancer patients. Backed by the co-founder and former chairman and chief executive officer of SAP, Dietmar Hopp, through dievini Hopp BioTech, MolecularHealth maintains offices in Basel, Switzerland; Heidelberg, Germany; Houston and New York. The company is led by a team of seasoned entrepreneurs, including the founding members of Generation Health, LION Bioscience, Model N Life Sciences and Xapien, and a group of scientists and technologists instrumental in the development of data analysis software for the Human Genome Project and clinical IT systems for leading U.S. health systems. MolecularHealth's collaborators include the University of Texas MD Anderson Cancer Center and the U.S. Food and Drug Administration (FDA).Media Contacts

Corporate Contact 

 Tony Russo, Ph.D., or Matt Middleman, M.D.Eric M. StoneRusso Partners, LLC

Vice President, Sales and MarketingT: 212-845-4251

T: (713) 834-9990T: 212-845-4272

eric.stone@molecularhealth.com tony.russo@russopartnersllc.com

 matt.middleman@russopartnersllc.com

  


'/>"/>

SOURCE MolecularHealth
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support
2. BioNeutral and Barnabas Health to Collaborate for Surgical Instrument Sterilization
3. Mercy/ROi and BD Collaborate to Improve Quality of Care and Reduce Costs
4. Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy
5. UCSF, Sanofi Collaborate to Find New Diabetes Cures
6. Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
7. DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs
8. FDA, Austen BioInnovation Institute to Collaborate on the Safety and Performance of Materials used in Medical Devices
9. Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis
10. Biospace Lab Collaborates With ImaBio Group to Develop a Unique X-Ray Tomographic Module for its Preclinical Imaging System
11. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 Lianluo Smart ... or "the Company") which develops, markets and sells ... China and international markets, ... Diagnosis and Treatment New Progress Forum, co-hosted by ... Guangdong Province , Guangdong Provincial People,s Hospital ...
(Date:12/2/2016)... , December 2, 2016 On ... down 1.36%; the Dow Jones Industrial Average edged 0.36% higher, ... 2,191.08, down 0.35%. Losses were broad based as six out ... has initiated research reports on the following Services equities: Myriad ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
(Date:12/2/2016)... OLD LYME, Conn. , Dec. 1, 2016 /PRNewswire/ ... consulting, has announced the honor of being selected as ... that include: Simpson Healthcare Executives Website at the PLATINUM ... Directed Conversations Training Module at the GOLD Level, and ... At Simpson Healthcare Executives, we are ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a ... its 60-day free trial program for all of the company’s desktop riser products. ... truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced dual ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame ... (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking ... prescription drug plan (Part D) need to make changes during this period order for ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
Breaking Medicine News(10 mins):